EMA Withdrawn: ImmunoGam (human hepatitis B immunoglobulin) — Cangene Europe Limited

View source ↗

Summary

EMA withdrew ImmunoGam, a human hepatitis B immunoglobulin product, from the market in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• ImmunoGam (human hepatitis B immunoglobulin)

Snippet

Status: Withdrawn. Therapeutic area: Immunization, Passive;Hepatitis B. MAH: Cangene Europe Limited. Decision date: 06/09/2010